Investigating sodium valproate as a treatment for McArdle disease in sheep

John Howell, E. Dunton, K.E. Creed, R.M.M. Quinlivan, C.A. Sewry

Research output: Contribution to journalArticle

9 Citations (Scopus)


© 2014. McArdle disease is due to an absence of the enzyme muscle glycogen phosphorylase and results in significant physical impairment in humans. We hypothesised that sodium valproate, an HDAC inhibitor, might have the ability to up-regulate the enzyme. We treated McArdle sheep with sodium valproate given enterically at 20-60 mg/kg body wt. Compared with untreated control animals, there was increased expression of phosphorylase in muscle fibres. The response was dose dependent and reached a maximum 2 hours after the application and increased with repeated applications. Improvement in mobility could not be demonstrated. These findings suggest that sodium valproate is a potential therapeutic treatment for McArdle disease.
Original languageEnglish
Pages (from-to)111-119
JournalNeuromuscular Disorders
Issue number2
Publication statusPublished - 2015


Dive into the research topics of 'Investigating sodium valproate as a treatment for McArdle disease in sheep'. Together they form a unique fingerprint.

Cite this